Press releases

You'll find below all the official Press Releases from Ceva.

2 October 2019

ProBioGen and Ceva Santé Animale sign an exclusive license agreement to produce vectorised poultry vaccines using AGE1.CR® production technology >

Berlin, Germany and Libourne, France 01st October 2019 - ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.

19 September 2019

Ceva brings together international experts in human cardiology and veterinary to stimulate innovation >

Cardio Symposium Human - Veterinary 2019 (September 17 - Milan)

11 September 2019

Ceva partners with Biotecon Diagnostics to introduce a real-time test kit to fight growing problem of salmonella on pig farms >

Libourne 10th September 2019 - A new real-time diagnostic kit that will help pig producers fight salmonella infections on their farms has been launched at the SafePork scientific symposium in Berlin.

10 September 2019

World Veterinary Association and Ceva Santé Animale enlarge the scope of the Global Animal Welfare Awards by adding new award categories >

Ceva Santé Animale (Ceva) and the World Veterinary Association (WVA) enlarge the scope of the Global Animal Welfare Awards to recognize veterinary technicians/nurses and veterinary schools in addition to veterinarians and veterinary students for their exemplary work in protecting and promoting Animal Welfare.

11 July 2019

Ceva’s acquisition of IDT swine vaccines delivers early promise with salmonella vaccine go-ahead in several European countries >

Libourne 8th July 2019 - Pig farmers in 12 European countries will now be able to protect their herds against the growing problem of Salmonella Typhimurium. Ceva will launch Salmoporc in Austria, Belgium, Czech Republic, Denmark, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Slovak Republic, United Kingdom through the remainder of 2019.

4 July 2019

Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split >

Libourne & Dessau 3rd July 2019 - Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) today announced that they have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva. The product portfolio will be transferred to Ceva branding as quickly as possible. A new Global innovation center focused on swine vaccines will be created within IDT’s exiting...

29 June 2019

Ceva Sante Animale makes Laval its global hub for innovation in the companion animal sector >

Laval, 25 June 2019 - Ceva, France’s largest veterinary biopharmaceutical company, has consolidated its investments in Mainland France, specifically in Laval, where it has established its global hub for innovation in the companion animal sector. This ultramodern campus, combining industrial, product and managerial innovation, required an investment of more than €25 million. The goal: to develop the...

17 May 2019

Ceva Santé Animale and IDT Biologika GmbH announce agreement for Ceva to acquire the IDT animal health business, expanding its global vaccine portfolio and boosting swine innovation >

Libourne & Dessau 17th. May 2019 - Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) have reached a provisional agreement for Ceva to acquire IDT’s veterinary biopharmaceutical portfolio and R&D activities, allowing IDT to focus on the manufacture of human biotechnology vaccines and pharmaceuticals for national and international markets. The deal is subject to approval by the Federal Cartel...

30 April 2019

WVA/Ceva Global Animal Welfare Awards highlight the special role veterinarians play in protecting the health and welfare of animals >

Veterinarians from around the world, who have made significant contributions to the promotion of animal welfare, have been honoured in the 2019 Global Animal Welfare Awards

29 April 2019

Ceva Santé Animale announces the launch of ForcerisTM, the first approved injectable combination of gleptoferron and toltrazuril in Europe >

25th April 2019, Libourne – ForcerisTM received the first marketing authorisation from the European Medicines Agency (EMA) for this innovative combination of gleptoferron and toltrazuril to treat neonatal piglets.

Back to top